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T2DM patients on insulin-only regimens with at least one
HbA1c value in the database and six months continuous eligi-
bility pre-post HbA1c index. Data on HbA1c, insulin regimen,
complications and demographic characteristics of all patients
were analyzed using descriptive statistics. RESULTS: Of 689
patients, 29% had HbA1c 7% (mean age 52 years; female 40%;
mean HbA1c 5.9%; basal-only 73%; basal-bolus 25%) while
71% had HbA1c 7% (mean age 51 years; female 41%; mean
HbA1c 9.3%; basal-only insulin 63%; basal-bolus insulin
34%). The nature and incidence of microvascular complications
in the two groups were: diabetic foot complications 2% and 6%
(p < 0.05), neuropathy 13% and 9%, retinopathy 9% and
13%, kidney disease 5% and 7% for patients with HbA1c <7%
and 7%, respectively. CONCLUSION: A sizable proportion
of T2DM patients were uncontrolled on their current insulin
regimen. This may reﬂect undue delay in insulin initiation and
intensiﬁcation by patients and providers. Moreover, a consider-
able proportion of patients at goal show signs of complications,
signifying the urgency of earlier insulin initiation and more
aggressive intensiﬁcation to ameliorate current sub-optimal gly-
cemic control.
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OBJECTIVE: To systematically review the literature and
published recommendations from four Health Technology
Assessment Agencies (HTAAs) in order to report what may
have contributed to the dearth of reimbursement of non-
injectable insulins. METHODS: Two independent researchers
systematically reviewed the published literature from 2003–
2007 using the MEDLINE, EMBASE, and Cochrane databases.
Publications of human trials involving non-injectable insulins
reported in any language were included. Keywords such as
Insulin, Oral OR Inhalation OR Aerosols OR Mist OR Spray
OR Sublingual OR Nebulizers OR Vaporizers OR Intranasal
OR Dermal OR Buccal with the indication of Diabetes Mellitus
Type 1 OR Diabetes Mellitus Type 2 were used. Clinical trials,
with at least one intervention being a non-injectable insulin,
were included. Exclusion criteria included inappropriate
research design, outcomes not reported and/or not extractable.
Listing decisions posted on the websites of the National Insti-
tute for Health and Clinical Excellence in the UK, the Scottish
Medicines Consortium, the Institute for Quality and Efﬁciency
in Health Care in Germany, and the Common Drug Review in
Canada were reviewed. RESULTS: Of 233 identiﬁed citations,
20 articles were included for full text review. Reported out-
comes included standard clinical efﬁcacy measures (e.g., post-
prandial glucose levels, HbA1c reduction) and tolerability. Few
articles (N = 3) reported outcomes such as patient preference
for treatment, general health-related quality of life, ﬁnal health
outcomes, and/or satisfaction. No studies were speciﬁcally
designed for reimbursement purposes. There was a paucity of
utility measures, the lack of which was the main criticism by
the HTAAs leading to either “not to list” or very restricted
listing recommendations. Other HTAA comments were the use
of secondary versus primary clinical outcomes and the absence
of adherence information. CONCLUSION: Clinical studies for
non-injectable insulins do not include adequate information
and/or outcomes that are required by decision makers for reim-
bursement recommendations.
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OBJECTIVE: To describe ﬁrst and second-line use of antidiabetic
drugs for management of type 2 diabetes in Italy, and to identify
potential predictors associated with the use of antihyperglycemic
drugs. METHODS: Primary care data were obtained from
400 Italian General Practitioners (GPs) providing information to
the Health Search/Thales Database (HSD). All patients with a
doctor-diagnosis of type 2 diabetes during the years 1996–2006
were selected. First and second-line drug therapy episodes were
evaluated by assessing the sequential fulﬁlment of prescriptions
of a particular antihyperglycemic drug class (or combination),
which followed the diabetes diagnosis. A sub-sample of diabetic
patients, with a registered diagnosis until the December 31, 2003
was also selected to evaluate the time-dependant clinical and
demographic characteristics associated with the use of different
antihyperglycemic drugs across the years 2004–2006. RESULTS:
A total of 19,561 diabetic patients had diabetes drug therapy
episodes between 1996 and 2006. Monotherapy with metformin
increased (from 4.1% in 1996 to 44.8% in 2006), while mono-
therapy with sulfonylureas decreased over time (from 32.7% to
23.9%) as ﬁrst line therapy. Thiazolidinedione (from 0.3% to
0.6%)and other oral antihyperglycemics (from 0.7% to 4.3%)
also raised over the period. Second-line drug therapy episodes
shown the same trend during study period with a substantial
increased use of thiazolidinedione (from 2.5% to 3.8%). As
regards prevalent patients characteristics, hypercholesteremia
and obesity were signiﬁcantly associated with the use of thiazo-
lidinediones while coronary artery disease, chronic renal and
hepatic failure were associated with insulin use. CONCLUSION:
Antihyperglycemic prescription patterns in Italy dramatically
changed from 1996 to 2006 with increased use of metformin and
decreased use of sulfonylureas. The introduction of thiazo-
lidinediones to the marketplace seems not change the manage-
ment of diabetes mellitus as ﬁrst line-treatment, although this
drug class is preferred in chronic patients particularly affected by
hypercholesteremia and obesity.
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OBJECTIVE: To proﬁle physician prescription Behavior for
patients with type 2 diabetes in a managed care setting.
METHODS: We used a retrospective cohort study design with
patient-de-identiﬁed national health claims databases (70+
million unique lives from January 1, 2098 through December
31, 2004). Patients with T2D were identiﬁed based on ICD-
9-CM codes, and were grouped into 6 cohorts (general practi-
tioner, other primary care specialist, internist, endocrinologist,
cardiologist, and other specialties) based on the practice spe-
cialty of physicians who prescribed the ﬁrst insulin for their
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